Compare WRBY & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRBY | VERA |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.5B |
| IPO Year | 2021 | 2021 |
| Metric | WRBY | VERA |
|---|---|---|
| Price | $24.18 | $53.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $25.43 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 5.6M | 1.9M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $850,580,000.00 | N/A |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | $13.06 | N/A |
| P/E Ratio | $10,595.57 | ★ N/A |
| Revenue Growth | ★ 14.55 | N/A |
| 52 Week Low | $13.63 | $18.53 |
| 52 Week High | $31.00 | $56.05 |
| Indicator | WRBY | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 80.23 |
| Support Level | $25.71 | $47.22 |
| Resistance Level | $27.29 | $56.05 |
| Average True Range (ATR) | 2.11 | 2.89 |
| MACD | -0.12 | 0.39 |
| Stochastic Oscillator | 41.78 | 85.61 |
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.